跳至主要内容
临床试验/NCT03710408
NCT03710408已完成不适用

Adverse Effects of Subcutaneous vs Intravenous Hydration on Older Acutely Admitted Patients: An Assessor-blinded, Non-inferiority RCT

Aalborg University Hospital2 个研究点 分布在 1 个国家目标入组 51 人开始时间: 2019年1月20日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
51
试验地点
2
主要终点
Incidence of adverse effects (dichotomous variable, blinded, non-inferior)

研究概览

简要总结

This study will evaluate the risk of adverse effects of intravenous hydration compared to subcutaneous hydration. Half of the patients will receive hydration by the subcutaneous route the other half by the intravenous route. In the subsequent 24 hours period the patients will be monitored for any sign of adverse effects.

详细描述

Adequate hydration is essential to humans, and is tightly regulated in the healthy adult by in- and output (i.e. thirst and urine production). This regulation is often hampered in the geriatric patient due to a decreased sensation of thirst and impaired kidney function. The risk of dehydration increases rapidly in the acutely ill geriatric patient with the growing fluid demand of fever and reduced ability to self-hydrate due to fatigue. Dehydration will often aggravate an acute illness creating a vicious circle. External rehydration is essential to stop or even prevent this downward spiral. Adequate hydration can be maintained or achieved by two different routes: oral intake or parenteral infusion. When oral hydration is insufficient, intravenous (IV) fluid infusion is the commonly used route. However, subcutaneous (SC) infusion of fluid, also known as hypodermoclysis, is an alternative route.

Several studies have compared SC hydration to IV hydration with the main outcome being laboratory test of hydration or subjective assessment scores. They all found similar effects on laboratory markers of hydration, which align with the theory of mass conservation. They also found a similar incidence of side effects between IV and SC hydration as secondary outcomes. The main drawback of these studies is methodological shortcomings. The lack of blinding introduces a large risk of bias on subjective outcome such as assessment scores and grading of side effects. Furthermore, the largest of the studies had a third of their patients switch groups diluting the result. A recent Cochrane review on achieving parenteral hydration found that the quality of included trials was low and future trials should prospectively register, have secure allocation concealment, adequate sample sizes and should be reported according to established standard.

This study will examine if subcutaneous (SC) hydration is a safe alternative to intravenous (IV) hydration in the geriatric patient in the Emergency Department, Acute Assessment Unit or Orthopedic Ward of Aalborg University Hospital. This will be achived by preforming an assessor-blinded, non-inferior, randomized controlled trial.

Relevant participants (see Eligibility Criteria) arriving at Aalborg University Hospital will be enrolled after informed consent. Baseline measurements will be obtained, and the participants will be randomized (1:1) to either intravenous or subcutaneous hydration. A sham setup will be use so both an intravenous access and a subcutaneous access will be visible on the patient, but only one of them will be active. For the next 24 hours the participants will regularly be evaluated by a nurse blinded to infusion for the presence of adverse effects.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Triple (Care Provider, Investigator, Outcomes Assessor)

盲法说明

To achieve assessor/care provider blinding, all participants will receive a sham needle (opposite of the randomization). This will not pierce the skin but just lay on top of the skin. Both the randomized and the sham needle will be covered by non-woven swabs before placement of the dressing. Both the active and the sham device is connected to an infusion set. The infusion tubes will be tangled at the top, just below the roller ball and drop counter. The entanglement will be covered by opaque dressing. This way it cannot be know which infusions tube is connected to the fluid bag, while it is still possible to control the infusion speed.

入排标准

年龄范围
65 Years 至 —(Older Adult)
性别
All
接受健康志愿者

入选标准

  • Medical patients admitted to Acute Assessment Unit (AAU). (All internal medicine patients are admitted here first, except highly specialized patients (e.g. ketoacidosis or severe cardiology conditions).
  • Orthopedic hip fracture patients admitted to the orthopedic ward.
  • Patients admitted to short term care.
  • Prescription of 0.5-2 liters of parenteral fluid over the next 24 hours.

排除标准

  • Red triage tag (severe ill patients)
  • Prescription of IV antibiotics or other treatment administrate intravenous
  • Severe dehydration (fluid requirements over 2 liters over 24 hours)
  • Known strict fluid restriction (cannot receive ½ liters of fluid infusion)
  • Severe general edema
  • Unable to give informed consent

结局指标

主要结局

Incidence of adverse effects (dichotomous variable, blinded, non-inferior)

时间窗: The participants will be observed for 24 hours after the start of infusion.

The incidence of adverse effects of hydration therapy (both serious and minor adverse effects) is the primary outcome measure of this study. Serious adverse effects will be defined as any consequence of infusion requiring treatment(e.g. diuretics, analgesic and antibiotics) Minor adverse effects will be defined as any of the following: * Reddening of the skin at infusion site larger than what is covered by dressing. * Painful swelling at infusion site. * Prolonged swelling at infusion site (more than two hours after end of infusion). * Itching. * Phlebitis without needing treatment. * Patient complaining of infusion related pain. * Failure of infusion. * Need of reinserting the infusion needle. * Accidental catheter removal by the patient. * Need for reducing of flow speed due to complaint from the patient. Swelling at infusion site, without discomfort or need for action, will not be evaluated as an adverse effect.

次要结局

  • Personal graded time spend on insertion of active device (ordered categorical variable, non-blinded).(During procedure.)
  • Presence of delirium (dichotomous variable, blinded)(Duration of observation (24 hours))
  • Incidence of adverse effects (dichotomous variable, blinded, superiority calculation)(The participants will be observed for 24 hours after the start of infusion.)
  • Participants evaluation of pain during fluid infusion through the active device (continuous variable, non-blinded)(Participants will evaluate this at the end of observation (24 hours after inclusion))
  • Incidence of serious adverse effects (total number of serious adverse effects (discrete variable, blinded)(The participants will be observed for 24 hours after the start of infusion)
  • Incidence of adverse effects (total number of adverse effects (discrete variable, not blinded)(The participants will be observed for 24 hours after the start of infusion.)
  • Participants evaluation of pain during inserting the active device (continuous variable, non-blinded).(During procedure.)
  • Death during hospitalization (dichotomous variable, blinded)(From inclusion to end of current admission. Cutoff is one month after inclusion.)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Mathias Aalkjær Brix Danielsen

Principal Investigator

Aalborg University Hospital

研究点 (2)

Loading locations...

相似试验

Subcutaneous vs Intravenous Hydration on Older Adults | 临床试验